ABSTRACT
RESUMO

INTRODUCTION
The action of phosphodiesterase type 5 inhibitor drug in the treatment of erectile dysfunction is recognized. One of its representatives, the sildenafi l, was initially developed as a vasodilator agent and employed in therapy of angina, however, by chance, it was discovered to act on the erectile dysfunction. Drugs like it are also used in pulmonary hypertension. Potential effects on the retina, heart and blood pressure were the targets of investigations (PACHE et al., 2002 Ciência Rural, v.44, n.8, ago, 2014. POLAK et al., 2003; AMERI et al., 2008; FORESTA et al., 2008; CORDELL et al., 2009) .
Phosphodiesterase type 5 inhibitor drugs, originally developed as antiaginal, are able to inhibit the hydrolysis of cGMP in the corpus cavernosum, increasing the concentration of this second messenger in the smooth wall of vessels. The event results in increased intravascular action of nitric oxide (NO) and vasodilation on the site. Nevertheless, PDE-5 inhibitors may also act by inhibiting the type-6 phosphodiesterase (PDE-6) present in the retina, with complications to the vision (ASHBY, 2006) . There is evidence that the sildenafi l citrate increases retinal blood circulation and it is speculated that the event is a consequence of increased blood fl ow, per vasodilation, similar to what happens within the corpus cavernosum sphere (GRUNWALD et al., 2001; POLAK et al., 2003; FORESTA et al., 2008) .
Identifying and quantifying some vasodilator activity on the retina, resulting from the action of the sildenafi l citrate, would bring signifi cant clinical benefi ts. When designing this research, the question was whether the sildenafi l citrate could cause changes in the hemodynamics and perfusion of the retina.
MATERIAL AND METHODS
The effects of sildenafi l were evaluated in 18 adult, male, albino, homozygote rabbits, of the New Zealand White breed, randomly divided into 3 groups of 6 animals, for drug treatment at a dose of 3.5mg kg -1 every 24 hours, for 7, 15 and 30 days, and in 9 control animals, totaling 27 subjects. For the selection of animals to compose the search, the Schirmer tear test (Schirmer tear test, Ophthalmos Ltda.), the biomicroscopy with slit-lamp (XL-1 Slitlamp ® , ShinNippon), the gonioscopy (Koe ppe medium diagnostic lens 18mm, Acular ® ), the applanation tonometry (Tono Pen XL ® , Medtronic), the indirect binocular ophthalmoscopy (indirect binocular ophthalmoscope FOH-5 ® , Eyetec S.A.) and the proof of dyeing by fl uorescein (Fluoresceína strips, Ophthalmos Ltda.) were performed as described by TALIERI et al. (2006) .
After 24 hours of the initial procedures, which included the evaluation of the intraocular pressure (IOP), basal mean arterial pressure (MAP), ocular perfusion pressure (PPO), ultrasonography and fl uorescein angiography, the treatment protocols were initiated with sildenafi l or placebo. The 3.5mg kg -1 dose of sildenafi l was employed at intervals of 24 hours, orally, for 7, 15 and 30 days. For the control group, 0.9% saline solution was employed, orally. One hour after the administration of sildenafi l citrate, on the 7 th , 15 th and 30 th days, the IOP, MAP and PPO were evaluated and the ultrasonography and fl uorescein angiography were performed. The evaluations were conducted always at the same time, beginning one hour after the treatments (sildenafi l and placebo). The IOP was evaluated by using a Tono Pen electronic applanation tonometer (Tono Pen XL ® , Medtronic), fi ve minutes after the instillation of 0.5% anesthetic proparacaine-based eye drop (Anestalcon ® , Alcon), kept refrigerated (5°C). For the MAP evaluation, the central ear artery was cannulated. A 24G catheter was used (BD Angiocath), attached to the skin with a drop of polymethylcyanoacrylate adhesive (Super Bonder, Henkel Ltda.). A multiparameter monitor (Monitor Multiparamétrico DIXTAL, DX 2010) was used. For the PPO, the method described by KIEL & HEUVEN (1995) was used, where: PPO=MAP-IOP.
For ultrasonography evaluation, equipment for ophthalmic ultrasonography (Ultrascan A/B, Alcon ® ) was employed, equipped with highfrequency sector transducer (20MHz) and the B-mode technique. The animals were contained manually and a thick layer of sterile acoustic gel was applied directly on the ocular surface, with the transducer positioned, being the position indication mark toward the side palpebral fi ssure. The external ophthalmic artery was identifi ed by using its curvature as point of reference, and its diameter was evaluated three times. The mean of three evaluations was employed as the basis for analysis (GONÇALVES, 2005) .
For fl uorescein angiography, 2mg kg (VIANA, 2007) . With the animal under anesthesia and cardiorespiratory functions monitored, the procedures for fl uorescein angiography were initiated. The marginal ear vein was cannulated by using a 24G catheter. The pupils were dilated by using 1% tropicamide drops (Tropicamide Colírio ® , Alcon). The head was positioned manually. A retinographer equipped with the Angioimage software (TRC 50-DX, Topcon) was used. Eye fundus was photographed. A 10% sodium fl uorescein (Fluoresceína sódica 100mg ml -1 injetável, Novartis) was applied, intravenously, in bolus, at a 10mg kg -1 dose. Serial images were taken for the angiogram of the arterial, arteriovenous and venous stages.
The data were evaluated by using the Kolmogorov Smirnov test concerning normality. Analyses of variance for repeated measurements, followed by post hoc Bonferroni test, were employed in the comparison between the means. A P<0.05 signifi cance level was adopted.
RESULTS
Concerning the IOP, no statistically signifi cant differences were found (P=0.41). The basal IOP mean was 12±6.22mm Hg -1 . At day 7 it was 8.66±0.81, at day 15 it was 9.83±1.47 and at day 30 it was 9.83±1.72mmHg.
The MAP basal mean was 84.83±7.13mmHg. At day 7, after administration of sildenafi l it was 78.50±17.49, at day 15 it was 73.33±11.72 and at day 30 it was 66.00±21.57, however, there was no statistically signifi cant difference (P=0.12).
Notwithstanding the non-statistical signifi cance (P=0.24), the PPO tended to decrease after treatment with sildenafi l citrate at the 7, 15 and 30 days. The basal mean was 72.83±12.85mmHg. At day 7 it was 69.83±17.37mmHg, at day 15 it was 65.50±11.96mmHg and at day 30 it was 56.16±21.11mmHg.
Concerning the ultrasonography, the mean of the external ophthalmic artery diameter before (basal) treatment was 2.545mm, differing signifi cantly (P=0.03) from the animals treated for 7 days, in which it was 2.865mm. Animals treated for 15 days also showed an increased external ophthalmic artery diameter, however no signifi cant difference was found when the mean basal values compared to the post-treatment ones (P=0.11). In animals treated for 30 days, there was signifi cant increase (P=0.01). The mean of the ophthalmic artery diameter was 2.90mm.
At the fl uorescein angiography (Figure 1  and Figure 2) , the arterial stage in the animals treated with sildenafi l for 7 and 15 days started more quickly, when compared to the arterial stage prior to treatment, however, a signifi cant difference (P=0.06) was not evident. The average time between the application of contrast and its onset in the retinal arteries, before treatment, was 5.00±1.09 seconds. In animals treated for 7 days it was 4.00±1.26 seconds and at day 15 it was 3.83±1.32 seconds. The time for the beginning of the arterial stage in animals treated for 30 days was 5.33±0.51, similarly to basal values. The average time for the onset of the arteriovenous stage before treatment was 6.83±1.16 seconds. In animals treated with sildenafi l for 7 days it was 5.33±1.21 seconds, in the animals treated for 15 days it was 5.16±1.16 seconds and in the animals treated for 30 days it was 6.33± 0.49 seconds. In animals treated for 15 days, the arteriovenous stage started more quickly than in other groups, presenting statistical signifi cance (P=0.01). The venous stage in the animals treated with sildenafi l for 7, 15 and 30 days started more quickly than in the untreated animals, however, statistical signifi cance (P=0.13) was not found. The average time for the onset before treatment was 10.33±3.83 seconds. In animals treated for 7 days it was 8.00±2.82 seconds and in animals treated for 15 days it was 6.16±1.72 seconds. In animals treated for 30 days, the average time for the beginning of the venous stage was 9.16±4.11 seconds.
DISCUSSION
No signifi cant changes concerning the IOP and the mean arterial pressure were found after treatments with sildenafi l citrate. The results corroborate the ones presented by POLAK et al. (2003) , which evaluated the same variables in men treated with a single dose of the drug. They do not differ from the ones presented by PACHE et al. (2002) , which notifi ed discrete decrease of the mean arterial pressure, with no evidences of heart or intraocular pressure changes. The IOP values found were kept according to the physiological values for rabbits (AMERI et al., 2008) .
This research chose to study the ophthalmic artery and not the retinal central artery or the ciliary arteries for technical reasons. The ophthalmic artery was easily located at the ultrasonography, enabling the visibilization of anatomical ultrasonography standard feasible of repeatability. The consulted literature reports that the ophthalmic artery tends to be more sensitive to the vasodilator action of PDE5 inhibitors (GRUNWALD et al., 2001; PARIS et al., 2001; FORESTA et al., 2008) .
Unlike reported by GRUNWALD et al. (2002) , whose study showed no change in vascular caliber, the increased diameter of the ophthalmic artery, found in the present study, may have resulted from the inhibitory action of sildenafi l citrate on PDE5 by continuous administration, which is also present in the arterioles of the corpus cavernosum penis, in the retina, in the lungs and in the coronary arteries. The PDE5 inhibition enhances the level of cGMP, intracellular messenger and nitric oxide, and mediates the vasodilation of arterioles in places such as the ones mentioned above (BENTLIN et al., 2005) .
The fact that the intraocular pressure has not shown signifi cant changes, despite the increased diameter of the external ophthalmic artery, it may be understood by the existence of intrinsic mechanisms of control of the intraocular pressure in that case. Blurred or momentary changes of the mean arterial pressure seem not to interfere in intraocular pressure (MAGGS, 2008) . In this study, there were no signifi cant changes in venous fl ow or in mean arterial pressure.
There was a PPO decrease in the animals treated with sildenafi l citrate, but with no statistical signifi cance. The event can be attributed to the ON increase by the drug, leading to vasodilation in the choroidal net, which would reduce the ocular perfusion pressure. The MAP decrease and the IOP decrease were summed to the PPO decrease. Despite the PPO decrease, increased speed of blood fl ow in the retina was observed, evidenced by the reduction of the onset time of the arterial, arteriovenous and venous stages.
It is known that the sildenafi l citrate causes signifi cant increase in the blood fl ow speed of the ophthalmic artery, dilation of the retina arteries and increase in the choroidal and retinal vessels fl ow (MCCULLEY et al., 2002; PACHE et al., 2002) . The fl uorescein angiography, however, had not been performed with such purpose, until this study was developed. SIU et al. (2000) evaluated the hemodynamic repercussion on ocular blood fl ow in patients who received 100mg of sildenafi l. The laser Doppler fl owmetry was used, but no signifi cant changes were found.
There are few publications on fl uorescein angiography in rabbits, and, in them, the description of the technique is slightly contemplated (AMERI et al., 2008; HELFENSTEIN et al., 2011) . The 10mg kg -1 dose of sodium fl uorescein used, and the application technique, through the marginal ear vein, met the description by AMERI et al. (2008) , almost fully.
For the arterial stage, the initial time of visibilization of fl uorescence on retinal arteries or the choroidal fi lling was considered together with the presence of fl uorescence in retinal arteries. The moment the dye was applied (SHIKANO & SHIMIZU, 1969) was considered time zero. In some animals, the beginning of fl uorescence happened in peripheral arteries, and not in the region of the optic nerve. The choroidal stage, oppositely to what is described for human patients, was not observed in this study.
For the arteriovenous stage, the complete fi lling of the retinal arterioles and venules was considered, as well as the presence of laminar fl ow in the veins, as proposed by GALÁN et al. (2006) , for fl uorescein angiography in sheep and goats. The authors mentioned that it was possible to identify the beginning of the arteriovenous stage when they visualize the contrast in venules close the optic disc.
For the venous stage, the presence of contrast was considered in all retinal veins, as well as throughout the choriocapillaris bed, keeping long term fl uorescence (GALÁN et al., 2006) .
In this study, the increased speed of blood fl ow in the retina was statistically signifi cant, with decreased time to the onset of the arteriovenous stage at days 7 th and 15 th after treatment with sildenafi l citrate, which agrees with the increased vascular fl ow in human choroid and retina, reported by POLAK et al. (2003) and HARRIS et al. (2008) . The increase can be attributed to the dilation of retinal arterial vessels, by increased release of nitric oxide, through PDE5 inhibition (WRIGHT, 2006) . Blood vessels are innervated by nitric oxide-producing neurons, which play an important role in local regulation of ocular blood fl ow, through the autonomic nervous system (GOLDSTEIN et al., 1996; TODA & NAKANISHI-TODA, 2007) .
The beginning of the venous stage decreased at day 15 of treatment with sildenafi l citrate. The increased speed of blood fl ow, in the animals treated with sildenafi l citrate, can be attributed to drug-generated retinal vasodilatation. The retinal vasodilatation, together with the decreased PPO and IOP, would be an excellent way to avoid the compensatory effects of chronic increase of IOP, as the retinal vasoconstriction example.
CONCLUSION
Based on the results obtained with the research, in the way it was designed, it is possible to admit that the sildenafi l citrate improves blood circulation in the retina of rabbits, by increasing the speed of blood fl ow and decreasing the perfusion pressure.
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